Skip to main content

Table 2 Clinical and genetic features of patients with malignant glioma with and without isocitrate dehydrogenase 1 (IDH1) mutation

From: Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients

   IDH1  
   Mutation (+) Mutation (-) P-value
AO Cases , number 20 10  
  Gender    
  Male, number 8 5 NS
  Female, number 12 5  
  Age, mean, years 48.3 44.4 NS
  Karnofsky performance status, mean score, % 94.5 89 NS
  Surgery    
  Total, number 16 6 NS
  Partial or biopsy, number 4 4  
  MGMT promoter    
  Methylation (+), number 19 5 0.0155
  Methylation (-), number 1 5  
  1p 19 co-deletion, number 11 7 NS
  Survival, median, months 72 69 NS
AOA Cases, number 12 14  
  Gender    
  Male, number 5 10 NS
  Female, number 7 4  
  Age, mean, years 46.4 48.7 NS
  Karnofsky performance status, mean score, % 97.5 96.4 NS
  Surgery    
  Total, number 5 8 NS
  MGMT promoter    
  Methylation (+), number 11 8 0.0479
  Methylation (-), number 1 6  
  1p 19q co-deletion, number 7 4 NS
  Survival, median, months 88 65 NS
AA Cases, number 12 28  
  Gender    
  Male, number 8 14 NS
  Female, number 4 14  
  Age,mean, years 41.7 44.3 NS
  Karnofsky performance status, mean score, % 90.8 78.9 NS
  Surgery    
  Total, number 4 4 NS
  Partial or biopsy, number 8 24  
  MGMT promoter    
  Methylation (+), number 9 9 0.0125
  Methylation (-), number 3 19  
  Survival, median, months 55 25 0.0786
GBM Cases, number 12 159  
  Tumor occurrence    
  Primary, number 4 155 0.0001
  Secondary, number 8 4  
  Gender    
  Male, number 6 99 NS
  Female, number 6 60  
  Age, mean, years 43.8 58.5 0.004
  Karnofsky performance status, mean score, % 87.5 79.7 NS
  Surgery    
  Total, number 3 71 NS
  Partial or biopsy, number 9 88  
  MGMT promoter    
  Methylation (+), number 10 63 0.0032
  Methylation (-), number 2 96  
  Survival, median, months 20 14 0.0051